The condition that affects about 2.5 million children worldwide is now understood to be caused by the duplication of genes in two genes involved in the development of the immune system.
But it has also been linked to the duplication in the genes that code for a protein that regulates the production of a neurotransmitter called serotonin, which can also be seen as a precursor to schizophrenia and other mental disorders.
In the latest edition of the journal Nature Genetics, a team of scientists at the University of Melbourne and the University at Albany have published the first genetic study of down syndrome and its symptoms in the first ever case of the syndrome being linked to serotonin.
They used mouse models to examine how down syndrome develops in different conditions and to look for possible pathways linking the syndrome to other disorders.
They also looked at whether the genetic variation found in Down syndrome could lead to a disorder, and if so, how it might manifest.
They found that Down syndrome is highly heterogeneous, with a number of different genetic variations, including some that were more common in Down’s syndrome patients, than in those who were unaffected.
The research also showed that there is a small subset of Down syndrome patients who are not affected by the condition, and the difference in the gene variant associated with Down syndrome in these patients was similar to the difference found in those with schizophrenia.
The scientists say their findings have important implications for the future of Down’s Syndrome.
“We believe that it is likely that down syndrome is a common genetic disorder in children, and it could be that down’s syndrome could be a genetic variant that has been present in this population for thousands of years,” said Dr Stephen Hock, a researcher at the Institute for Molecular Biology at the Melbourne Institute of Medical Research.
“It may not be that there are some specific genes that are involved in Down Syndrome, but there may be more genes involved.”
This is a very interesting paper that opens up the door to new insights in the understanding of this disease, as well as potentially for future therapies and the development for novel drugs to treat Down syndrome.
“Down syndrome was discovered in 1998 in Australia by two Australians, Dr James McGovern and his partner, Dr Jennifer Purdom, who found a rare mutation in a gene that encodes a protein involved in serotonin production.”
If this mutation causes the brain to make a deficiency of serotonin, it is a disease of the central nervous system,” said Purdo.
The gene was first identified in the 1990s, and more than 30,000 people have been diagnosed with Down’s.
A large proportion of these people have Down’s because of the damage caused by their mother’s Down syndrome.
The first cases of Down, known as MTHFR mutations, were first identified by geneticist and neuroscientist James McPherson in 2001.
The McPhersons were the first to identify a gene variant that could lead people with Down Syndrome to develop schizophrenia.
But in the early 2000s, a study by the McPheresons showed that the disorder was more common among MTHF variants than among healthy people.
This led them to wonder if there were any genes that could cause the disorder, or if the variant was associated with other conditions.
This lead to the discovery of the gene variants MTHFS and DMR2.MTHFR is a key enzyme in the immune response, and DSR2 is a molecule that helps the body to make serotonin, a neurotransmitter.
It is believed that mutations in these two genes may be linked to Down Syndrome.
The researchers found that a gene mutation in one of these two enzymes was associated, with about 25 per cent of the Down syndrome cases being linked with schizophrenia, compared with less than 5 per cent for the control group.
This is likely because the DSR enzymes also cause the production and clearance of a hormone that is associated with schizophrenia symptoms.”
These two genes are involved, but not in the same way, in the pathway that causes schizophrenia,” said Hock.”
They are linked to each other, but the pathways that cause schizophrenia are very different from the pathways causing Down syndrome, so it’s not necessarily that one causes the other.
“Dr McPhea said the findings from the study would help to inform a better understanding of the disorder.”
There is now much more understanding about the genes involved with Down,” he said.”
So this research will hopefully help to identify the gene that is involved and will help to develop treatments for Down.
“He said there was still much to learn about how Down syndrome develops, and said the study did not provide any definitive answers.”
The best way to diagnose Down syndrome would be through blood tests,” he explained.”
People will be better at predicting Down syndrome if they are given blood tests to see how well they can distinguish between Down syndrome and normal children.
“Our results are very encouraging but it’s important that we learn more about the genetic and